Therapeutic Response

BRCA1 pathogenic variants status confers therapeutic sensitivity to Rucaparib in patients with Peritoneal Serous Carcinoma.

Statements

Source and description
Rubraca (rucaparib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.